DE60126248D1 - Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs - Google Patents
Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebsInfo
- Publication number
- DE60126248D1 DE60126248D1 DE60126248T DE60126248T DE60126248D1 DE 60126248 D1 DE60126248 D1 DE 60126248D1 DE 60126248 T DE60126248 T DE 60126248T DE 60126248 T DE60126248 T DE 60126248T DE 60126248 D1 DE60126248 D1 DE 60126248D1
- Authority
- DE
- Germany
- Prior art keywords
- breast cancer
- diagnosis
- treatment
- prophylaxis
- membrane proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 4
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 108010052285 Membrane Proteins Proteins 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000009509 drug development Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Optics & Photonics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0004576.5A GB0004576D0 (en) | 2000-02-25 | 2000-02-25 | Proteins |
GB0004576 | 2000-02-25 | ||
GB0031341A GB0031341D0 (en) | 2000-12-21 | 2000-12-21 | Protein |
GB0031341 | 2000-12-21 | ||
PCT/GB2001/000748 WO2001062784A2 (en) | 2000-02-25 | 2001-02-21 | Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60126248D1 true DE60126248D1 (de) | 2007-03-15 |
DE60126248T2 DE60126248T2 (de) | 2007-07-05 |
Family
ID=26243736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60126248T Expired - Fee Related DE60126248T2 (de) | 2000-02-25 | 2001-02-21 | Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs |
Country Status (15)
Country | Link |
---|---|
US (3) | US20030130214A1 (de) |
EP (2) | EP1257285B1 (de) |
JP (1) | JP2003524017A (de) |
KR (1) | KR100740761B1 (de) |
CN (1) | CN100384875C (de) |
AT (1) | ATE352311T1 (de) |
AU (3) | AU2001233913A1 (de) |
BR (1) | BR0108659A (de) |
CA (1) | CA2399999A1 (de) |
DE (1) | DE60126248T2 (de) |
ES (1) | ES2279801T3 (de) |
HK (1) | HK1056692A1 (de) |
IL (1) | IL151448A0 (de) |
NZ (1) | NZ520967A (de) |
WO (2) | WO2001062914A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7054758B2 (en) * | 2001-01-30 | 2006-05-30 | Sciona Limited | Computer-assisted means for assessing lifestyle risk factors |
GB0125072D0 (en) * | 2001-10-18 | 2001-12-12 | Oxford Glycosciences Uk Ltd | Protein |
AU2003209459A1 (en) * | 2002-03-06 | 2003-09-16 | Hybrigenics | Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11 |
US20040033530A1 (en) * | 2002-04-08 | 2004-02-19 | Awrey Donald E. | High throughput purification, characterization and identification of recombinant proteins |
GB0208331D0 (en) * | 2002-04-11 | 2002-05-22 | Oxford Glycosciences Uk Ltd | Proteins |
FR2846426B1 (fr) * | 2002-10-28 | 2004-12-10 | Bio Merieux | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
CN1745094A (zh) * | 2002-12-06 | 2006-03-08 | 新加坡综合医院有限公司 | 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途 |
CA2538300A1 (en) * | 2003-09-22 | 2005-03-31 | Green Peptide Co., Ltd. | Prognosis in cancer patients vaccinated with a cancer antigen peptide-associated agent |
EP1693069B1 (de) | 2003-10-10 | 2013-07-24 | Chugai Seiyaku Kabushiki Kaisha | Mittel zur behandlung von soliden tumoren |
JP2007520217A (ja) * | 2004-01-27 | 2007-07-26 | コンピュゲン ユーエスエイ,インク. | 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法 |
KR100763902B1 (ko) * | 2004-02-20 | 2007-10-05 | 삼성전자주식회사 | 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법 |
WO2008104803A2 (en) * | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
KR101398079B1 (ko) * | 2011-10-10 | 2014-05-27 | 재단법인 의약바이오컨버젼스연구단 | 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법 |
CN104447975A (zh) * | 2014-11-18 | 2015-03-25 | 深圳市人口和计划生育科学研究所 | 一种提取人肿瘤细胞膜蛋白的方法 |
WO2017011375A1 (en) * | 2015-07-10 | 2017-01-19 | University Of Iowa Reseaarch Foundation | Bst-2 as a therapeutic target and a predictive/prognostic bio-signature for breast cancer growth and metastasis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002508652A (ja) * | 1996-08-23 | 2002-03-19 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | 新規なヒト増殖因子 |
DE19813839A1 (de) * | 1998-03-20 | 1999-09-23 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Brusttumorgewebe |
CZ20014718A3 (cs) * | 1999-06-30 | 2003-01-15 | Corixa Corporation | Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic |
-
2001
- 2001-02-21 JP JP2001562565A patent/JP2003524017A/ja active Pending
- 2001-02-21 CN CNB018084885A patent/CN100384875C/zh not_active Expired - Fee Related
- 2001-02-21 WO PCT/GB2001/000729 patent/WO2001062914A1/en not_active Application Discontinuation
- 2001-02-21 IL IL15144801A patent/IL151448A0/xx unknown
- 2001-02-21 DE DE60126248T patent/DE60126248T2/de not_active Expired - Fee Related
- 2001-02-21 AU AU2001233913A patent/AU2001233913A1/en not_active Abandoned
- 2001-02-21 EP EP01905965A patent/EP1257285B1/de not_active Expired - Lifetime
- 2001-02-21 NZ NZ520967A patent/NZ520967A/en unknown
- 2001-02-21 AU AU2001233929A patent/AU2001233929C1/en not_active Ceased
- 2001-02-21 BR BR0108659-6A patent/BR0108659A/pt not_active IP Right Cessation
- 2001-02-21 ES ES01905965T patent/ES2279801T3/es not_active Expired - Lifetime
- 2001-02-21 WO PCT/GB2001/000748 patent/WO2001062784A2/en active IP Right Grant
- 2001-02-21 AT AT01905965T patent/ATE352311T1/de not_active IP Right Cessation
- 2001-02-21 AU AU3392901A patent/AU3392901A/xx active Pending
- 2001-02-21 KR KR1020027011130A patent/KR100740761B1/ko not_active IP Right Cessation
- 2001-02-21 CA CA002399999A patent/CA2399999A1/en not_active Abandoned
- 2001-02-21 EP EP01905949A patent/EP1259604A1/de not_active Withdrawn
- 2001-02-23 US US09/791,392 patent/US20030130214A1/en not_active Abandoned
-
2002
- 2002-08-23 US US10/227,616 patent/US20030099662A1/en not_active Abandoned
-
2003
- 2003-12-16 HK HK03109173.7A patent/HK1056692A1/xx not_active IP Right Cessation
-
2006
- 2006-08-24 US US11/509,841 patent/US20070212368A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR0108659A (pt) | 2002-11-05 |
EP1257285A2 (de) | 2002-11-20 |
IL151448A0 (en) | 2003-04-10 |
WO2001062784A3 (en) | 2002-01-31 |
KR100740761B1 (ko) | 2007-07-19 |
JP2003524017A (ja) | 2003-08-12 |
KR20030007440A (ko) | 2003-01-23 |
EP1259604A1 (de) | 2002-11-27 |
AU2001233929C1 (en) | 2006-03-02 |
EP1257285B1 (de) | 2007-01-24 |
US20030099662A1 (en) | 2003-05-29 |
CN100384875C (zh) | 2008-04-30 |
US20030130214A1 (en) | 2003-07-10 |
DE60126248T2 (de) | 2007-07-05 |
CN1426307A (zh) | 2003-06-25 |
HK1056692A1 (en) | 2004-02-27 |
US20070212368A1 (en) | 2007-09-13 |
AU2001233913A1 (en) | 2001-09-03 |
AU3392901A (en) | 2001-09-03 |
WO2001062784A2 (en) | 2001-08-30 |
ES2279801T3 (es) | 2007-09-01 |
CA2399999A1 (en) | 2001-08-30 |
ATE352311T1 (de) | 2007-02-15 |
WO2001062914A1 (en) | 2001-08-30 |
AU2001233929B2 (en) | 2005-09-08 |
NZ520967A (en) | 2004-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE352311T1 (de) | Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs | |
ATE453653T1 (de) | Platinkomplexe zur behandlung von tumoren | |
ATE397754T1 (de) | Verwendung von sc6 für die diagnose und behandlung von bustkarzinom | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
ATE440536T1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
ATE526991T1 (de) | Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen | |
ATE302278T1 (de) | Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen | |
ATE414089T1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
DE60027762D1 (de) | Diagnose und behandlung von arthritischen erkrankungen | |
NO20055741D0 (no) | Nye kjemiske forbindelser | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
ATE419516T1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
ATE338142T1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
DE60026150D1 (de) | Diagnostika und therapeutika für osteoporose | |
ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
DE60113968D1 (de) | Diagnose von brustkrebs unter verwendung von bcmp-7 als marker | |
DE60226324D1 (de) | Glykopeptide, deren herstellung und verwendung in der diagnose oder behandlung von multipler sklerose | |
DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
DE69918541D1 (de) | Verwendung von nmda antagonisten zur behandlung des reizkolons | |
ATE390435T1 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie | |
DE69931644D1 (de) | Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen | |
ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
DE60020970D1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen | |
EA200600012A1 (ru) | Полиморфизм человеческого гена nbs1, полезный для диагностики наследственной предрасположенности к раку |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |